Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.80 Consensus Price Target from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has earned an average recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $22.80.

LXEO has been the subject of several recent analyst reports. Royal Bank of Canada reduced their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, March 25th. Chardan Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, March 25th. HC Wainwright restated a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday, March 26th. Finally, Leerink Partners decreased their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Monday, March 24th.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LXEO. Charles Schwab Investment Management Inc. lifted its holdings in shares of Lexeo Therapeutics by 107.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock worth $577,000 after buying an additional 33,013 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of Lexeo Therapeutics by 121.5% in the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after buying an additional 7,803 shares in the last quarter. PDT Partners LLC bought a new position in Lexeo Therapeutics during the third quarter valued at approximately $241,000. Finally, Janus Henderson Group PLC grew its holdings in Lexeo Therapeutics by 18.9% during the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after buying an additional 599,203 shares in the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock opened at $2.34 on Wednesday. The business has a 50 day moving average of $3.82 and a 200-day moving average of $6.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a 1 year low of $2.27 and a 1 year high of $19.50. The company has a market capitalization of $77.68 million, a P/E ratio of -0.74 and a beta of 1.52.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09. On average, equities research analysts predict that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.